The Broad Institute licenses CRISPR/Cas9 to Evotec

Genomeweb, 6 July 2016

In a non-exclusive deal, drug development company Evotec has licensed the CRISPR/Cas9 technology from the Broad Institute.  Evotec will use the technology in drug-development/target identification and with its post-phenotypical screening target deconvolution platform.

Author: Advanced Analytical

Advanced Analytical Technologies, Inc. (AATI) simplifies complex genomics workflows to accelerate research and discovery in pharmaceuticals, life science, biofuels, biotechnology and healthcare.

Leave a Reply